Abstract: The present invention relates to the use of probiotics to control the inflammatory process of the colon in subjects with structural modifications of the colon wall, preferably in subjects with diverticulosis, and affected by diverticular disease.
Type:
Grant
Filed:
December 15, 2017
Date of Patent:
February 13, 2024
Assignee:
ALFASIGMA S.P.A.
Inventors:
Andrea Biffi, Walter Fiore, Ruggero Rossi
Abstract: The present invention relates to the use of a composition comprising bacteria to increase the intestinal production of butyric acid, folic acid or niacin and/or to decrease the intestinal production of succinic acid. Moreover, the present invention relates to the use of said composition for the treatment and/or prevention of an intestinal butyrate- and/or succinate-dependent pathological condition. In particular, for the treatment and/or the prevention of intestinal inflammation, diarrhoea, ulcerative colitis or intestinal colopathies.
Type:
Grant
Filed:
September 5, 2014
Date of Patent:
December 12, 2023
Assignee:
ALFASIGMA S.P.A.
Inventors:
Simone Domenico Guglielmetti, Ruggero Rossi, Walter Fiore, Andrea Biffi
Abstract: Compositions, food products, methods and systems for use in increasing the blood bioavailability of amino acids derived from proteins, preferably proteins of plant origin, comprising a mixture M comprising or, alternatively, consisting of at least one bacterial strain, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-S01™ DSM 26760, and possibly. The compositions food products, methods and systems o the disclosure, can further comprise at least one protein, preferably proteins of plant origin, or a peptide or an amino acid, and in particular includes a food product comprising proteins, preferably of plant origin, and said mixture M of at least one bacterial strain.
Abstract: The present invention relates to the use of a composition based on bacteria and/or yeasts and/or other microorganisms, taken singularly or in combination, for the treatment of abdominal pain by administering to a patient suffering from Irritable Bowel Syndrome (IBS). In particular, the bacteria comprise Lactobacillus paracasei DG strain deposited with the deposit number CNCMI 1572.
Type:
Grant
Filed:
June 8, 2017
Date of Patent:
September 12, 2023
Assignee:
ALFASIGMA S.P.A.
Inventors:
Andrea Biffi, Walter Fiore, Ruggero Rossi
Abstract: The present invention describes a pharmaceutical and/or nutritional composition comprising methylfolate in the form of granules, together with a carnitine derivative salt, pharmaceutically acceptable excipients, and optionally other pharmaceutical or nutraceutical active ingredients. The composition is useful for oral administration. The invention also relates to the process for obtaining the composition comprising methylfolate in the form of granules and the use thereof for the treatment of disorders associated with a reduction of methylfolate, wherein methylfolate is useful.
Type:
Application
Filed:
May 10, 2021
Publication date:
June 15, 2023
Applicant:
ALFASIGMA S.P.A.
Inventors:
Mauro Marzi, Mose' Santaniello, Pietro Meloni, Marta Paris, Fabrizio Giorgi, Emilio Merlo Pich
Abstract: The present invention relates to methods and pharmaceutical compositions for treatment of all symptoms of gastroparesis in a human patient, the method comprising administering to the human patient between about 0.5 mg/day to about 30 mg/day, about 0.5 mg/day to about 15 mg/day, about 0.5 mg/day to about 5 mg/day, or about 5 mg/day, of velusetrag or a pharmaceutically-acceptable salt thereof.
Abstract: The invention described herein is directed to the use of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in which said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.
Type:
Grant
Filed:
June 19, 2020
Date of Patent:
September 6, 2022
Assignee:
ALFASIGMA S.P.A.
Inventors:
Mariagrazia Grilli, Pier Luigi Canonico, Aleardo Koverech
Abstract: The invention relates to gel compositions comprising pharmaceutical active ingredients. The composition comprises xyloglucan at a concentration between 0.1% and 10.0% by total weight of the composition, together with a primary alcohol at a concentration between 20.0 and 50.0% by total weight of the composition. The invention also describes a process for the preparation of the composition and its use in the treatment of pathologies wherein a controlled release of the active principle is useful.
Type:
Application
Filed:
June 11, 2020
Publication date:
August 4, 2022
Applicant:
ALFASIGMA S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Paola MAFFEI, Cristiana Bruno, Mascia Federici, Clelia Dispenza, Maria Antonietta Sabatino
Abstract: The present invention describes a mucoadhesive composition comprising chondroitin sulfate, xyloglucan and glycerol for use in the treatment and prevention of gastroesophageal reflux. It is also described a process for preparing such composition, a dosage form for its administration and a kit comprising the same.
Type:
Grant
Filed:
September 18, 2018
Date of Patent:
February 8, 2022
Assignee:
ALFASIGMA S.P.A.
Inventors:
Paola Maffei, Marco Mascagni, Giuseppe Claudio Viscomi
Abstract: Disclosed herein are methods of treating a patient having an intestinal disorder, the methods comprising: administering to a patient in need thereof a pharmaceutical composition comprising a hydrate or solvate form of rifaximin in polymorphic form ?, alone or in a mixture with other crystalline, hydrate, solvate or amorphous forms of rifaximin, in gastroresistant microgranules, wherein the rifaximin is administered at a dose of at least 800 mg per day for a period of at least 7 days.
Type:
Application
Filed:
September 17, 2020
Publication date:
August 12, 2021
Applicant:
ALFASIGMA S.P.A.
Inventors:
Giuseppe Claudio VISCOMI, Paola MAFFEI, Giuseppe BOTTONI, Maria GRIMALDI
Abstract: The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)-based antibody drug conjugates particularly with antibodies directed to ErbB, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.
Type:
Application
Filed:
March 27, 2018
Publication date:
May 6, 2021
Applicant:
ALFASIGMA S.P.A.
Inventors:
Loredana Vesci, Rita De Santis, Ferdinando Maria Milazzo, Giuseppe Giannini, Maurizio Taddei, Valentina Faltoni, Elena Petricci
Abstract: The invention described herein is directed to the use of acetyl L-carnitine, or propionyl L-carnitine, or a salt thereof, for preparing a medicament for increasing neurogenesis in neural tissue; in which said increased neurogenesis is useful for preventing central nervous system disorders due to ageing or genetic predisposition.
Type:
Application
Filed:
June 19, 2020
Publication date:
October 15, 2020
Applicant:
ALFASIGMA S.P.A.
Inventors:
Mariagrazia GRILLI, Pier Luigi CANONICO, Aleardo KOVERECH
Abstract: The present invention refers to a new strain belonging to the species Lactobacillus paracasei able to convert linoleic acid into conjugated linoleic acid. The present invention refers also to nutritional or food preparations and/or pharmaceutical compositions, comprising the strain Lactobacillus paracasei, useful in the treatment and/or prevention of pathologies and/or physiological states related to conjugated linoleic acid deficiency or in the cases wherein the use of a probiotic is beneficial.
Type:
Grant
Filed:
October 1, 2019
Date of Patent:
October 6, 2020
Assignee:
ALFASIGMA S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Annalisa Sforzini, Pierluigi Mangino, Marina Elli
Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ? useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.
Type:
Grant
Filed:
March 4, 2019
Date of Patent:
July 7, 2020
Assignee:
ALFASIGMA S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Manuela Campana, Donatella Confortini, Maria Barbanti, Dario Braga
Abstract: The present invention refers to a new strain belonging to the species Lactobacillus paracasei able to convert linoleic acid into conjugated linoleic acid. The present invention refers also to nutritional or food preparations and/or pharmaceutical compositions, comprising the strain Lactobacillus paracasei, useful in the treatment and/or prevention of pathologies and/or physiological states related to conjugated linoleic acid deficiency or in the cases wherein the use of a probiotic is beneficial.
Type:
Application
Filed:
October 1, 2019
Publication date:
January 30, 2020
Applicant:
ALFASIGMA S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Annalisa Sforzini, Pierluigi Mangino, Marina Elli
Abstract: The present invention describes a mucoadhesive composition comprising chondroitin sulfate, xyloglucan and glycerol for use in the treatment and prevention of gastroesophageal reflux. It is also described a process for preparing such composition, a dosage form for its administration and a kit comprising the same.
Type:
Application
Filed:
September 18, 2018
Publication date:
October 17, 2019
Applicant:
ALFASIGMA S.P.A.
Inventors:
Paola Maffei, Marco Mascagni, Giuseppe Claudio Viscomi
Abstract: The present invention describes a new crystalline form of rifaximin, characterized in that it is a solvated form of rifaximin called rifaximin ? The invention also describes a process for the preparation of rifaximin ?, a pharmaceutical composition comprising said rifaximin form, and its use for treating inflammations and infections.
Type:
Grant
Filed:
February 27, 2018
Date of Patent:
October 1, 2019
Assignee:
ALFASIGMA S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Paola Maffei, Annalisa Sforzini, Fabrizia Grepioni, Laura Chelazzi
Abstract: The present invention relates to homogeneous formulations comprising omega-3 polyunsaturated fatty acids (n-3 PUFA) and resveratrol for oral administration, in which the resveratrol is solubilized in a solvent system consisting of omega-3 polyunsaturated fatty acids (n-3 PUFA), or their alkyl esters, and a ionic emulsifier. The composition according to the present invention can be formulated as food or nutritional supplement or medicament in the prevention or treatment of cardiovascular diseases due to lipid metabolism disorders and increased platelets aggregation, as well as damages due to free radicals and/or viral diseases.
Abstract: The object of the invention consists of pharmaceutical formulations containing rifaximin in the shape of microgranules made gastroresistant by an insoluble polymer at pH values between 1.5 and 4.0 and soluble at pH values between 5.0 and 7.5, by their preparation and by their use in the manufacture of medicinal preparations useful in the treatment of inflammatory bowel diseases (IBD) and mainly Crohn's disease.
Type:
Grant
Filed:
October 2, 2013
Date of Patent:
May 14, 2019
Assignee:
ALFASIGMA S.P.A.
Inventors:
Giuseppe Claudio Viscomi, Ernesto Palazzini, Villiam Zamboni, Maria Rosaria Pantaleo
Abstract: Polyols stabilize polymorphous form of rifaximin, in particular the ? form. When polyols having at least two hydroxy groups are added to rifaximin powder, polymorph ? is stable and remains stable in time independently from the environment humidity. In this invention a method to prepare formulations constituted by pure and stable polymorphous forms able to give a pharmaceutical product is described.
Type:
Grant
Filed:
May 12, 2016
Date of Patent:
May 7, 2019
Assignee:
ALFASIGMA S.P.A.
Inventors:
Paola Maffei, Milena Bachetti, Giuseppe Bottoni, Giuseppe Claudio Viscomi